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Available online 13 May 2016An increase in procollagen type I amino-terminal propeptide (PINP) early after teriparatide initiation was shown
to correlate with increased lumbar spine areal BMD and is a good predictor of the anabolic response to
teriparatide. Few data exist correlating PINP and bone microstructure, and no data exist in patients on
teriparatide following prior potent antiresorptive treatment. This exploratory analysis aimed to investigate the
effects of teriparatide on cancellous bone microstructure and correlations of bone markers with microstructure
in alendronate-pretreated patients. This was a post hoc analysis of changes in bone markers and three-dimen-
sional indices of bone microstructure in paired iliac crest biopsies from a prospective teriparatide treatment
study in postmenopausal women with osteoporosis who were either treatment-naïve (TN, n = 16) or
alendronate-pretreated (ALN, n = 29) at teriparatide initiation. Teriparatide (20 μg/day) was given for
24months; biopsies were taken at baseline and endpoint, and serum concentrations of PINP and type 1 collagen
cross-linked C-telopeptide (βCTX) were measured at intervals up to 24 months. In the TN and ALN groups, re-
spectively, mean (SD) increases in three-dimensional bone volume/tissue volume were 105 (356)% (P =
0.039) and 55 (139)% (P b 0.005) and trabecular thickness 30.4 (30)% (P b 0.001) and 30.8 (53)% (P b 0.001).
No signiﬁcant changes were observed in trabecular number or separation. In the ALN patients, 3-month change
of neither PINP norβCTX correlatedwith indices of cancellous bonemicrostructure. However, 12-month changes
in biochemical bone markers correlated signiﬁcantly with improvements in bone volume/tissue volume, r =
0.502 (P b 0.01) and r = 0.378 (P b 0.05), trabecular number, r = 0.559 (P b 0.01) and r = 0.515 (P b 0.01),
and reduction of trabecular separation, r=−0.432 (P b 0.05) and r=−0.530 (P b 0.01), for PINP and βCTX, re-
spectively. We conclude that cancellous bone microstructure improved with teriparatide therapy irrespective of
prior antiresorptive use.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Teriparatide treatment stimulates bone formation and reduces frac-
ture rates in postmenopausal women with osteoporosis [1,2]. The in-
crease in BMD is associated with various structural improvements
resulting in improved biomechanical properties of the bone [3–7].
Teriparatide also rapidly increases biochemical markers of bone forma-
tion, followed by an increase of resorption markers, and data suggest
that the increases in biochemical markers correlate with indices oficine, Division of Endocrinology
rplatz 15, A-8036 Graz, Austria.
ahrleitner-Pammer).
. This is an open access article underbone formation, such as BMD, quantitative CT-based ﬁnite element
analysis, or dynamic histomorphometry [7–13]. Among the different
markers, serum procollagen type I amino-terminal propeptide (PINP),
which reﬂects collagen formation, appeared to be the most sensitive
for predicting BMD change in this setting [9,11,14]. Early increase of
PINP after the initiation of teriparatide treatment has been demonstrat-
ed to positively correlate with the increase of lumbar spine areal BMD
[8,9,15]. Consequently, PINP response has been proposed to be predic-
tive for the individual bone-building capability of teriparatide.
While substantial data exist on these correlations betweenbiochem-
ical markers and X-ray-based bone quality indices, few reports
have investigated the relationship between such markers and
histomorphometric indices of bone microstructure. Teriparatidethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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connectivity, improved cancellous bonemorphology, and increased cor-
tical bone thickness [16]. Some of these structural improvements were
correlated with early increases of biochemical markers measured in
the same teriparatide-treated patients [3]. Moreover, teriparatide-in-
duced early increase of PINP was correlated with subsequent increases
in indices of dynamic histomorphometry suggesting an anabolic re-
sponse of teriparatide [10,13].
However, the microstructure-only analysis was performed in post-
menopausal women with osteoporosis who were treated for less than
the currently recommended full duration of teriparatide treatment
(mean 19months versus 24months) [3,16] and in thosewith nomean-
ingful pretreatment with antiresorptives [16]. These may be important
limitations, because some observations suggest that pretreatment
with potent antiresorptives such as alendronate may blunt the PINP re-
sponse and the lumbar spine BMD increase in the initial treatment
phase, for up to 6months [5,7,17–20]. Lumbar spine BMD is rich in can-
cellous bone, characterized by rapid turnover, andmay be amore sensi-
tive early marker of changes in bone formation than bone areas
containing large amounts of cortical bone, such as the femoral neck.
There are currently nodata available to indicatewhether long-termpre-
treatment with a potent antiresorptive such as alendronate interacts
with teriparatide with respect to its effects on cancellous bone micro-
structure. It is also not known whether alendronate pretreatment af-
fects the correlations between biochemical markers of turnover and
microstructural changes. We have demonstrated in our previous study
that increases of dynamic bone formation markers with teriparatide
are not meaningfully different between alendronate pretreated and
treatment-naïve patients [16], but no data exist on comparisons for mi-
crostructural changes. Thus, the aim of this analysis was to investigate
the effects of teriparatide on cancellous bone microstructure, either
with or without alendronate pretreatment, and to examine the correla-
tions between bone markers and microstructure in patients pretreated
with alendronate as a means to predict patient response to treatment.2. Materials and methods
2.1. Patients and treatments
The present study was a post hoc analysis from a prospective
teriparatide treatment study (ClinicalTrials.gov: NCT00191893) carried
out in two study centers in Graz, Austria, and Prague, Czech Republic.
The study design, patient characteristics and methods have been de-
scribed previously [10,21], and are summarized brieﬂy here. Prior to
study, all patients signed informed consent to the treatment and inves-
tigation protocol, which was approved by the Institutional Review
Board for Research Involving Human Subjects at the two study centers
involved.
The single-arm teriparatide study included 66 ambulatory postmen-
opausalwomenwith osteoporosis at either the total hip or lumbar spine
(T-score ≤−2.5) andwhowere aged at least 55 years. Patientswere ex-
cluded if they had a history of any secondary cause of osteoporosis, ma-
lignant neoplasm in the previous 5 years, nephrolithiasis or urolithiasis
in the previous 2 years, abnormal thyroid function, active liver disease,
impaired renal function, treatment with androgens or other anabolic
steroids, treatment with vitamin D N 50.000 IU/week or active vitamin
D analogs, or treatment with raloxifene, calcitonin, ﬂuoride, progestins,
estrogens, estrogen analogs, agonists or antagonists, selective estrogen
receptor modulators, tibolone, systemic corticosteroids, or
bisphosphonates other than alendronate in the previous 3 years.
Of the 66 enrolled patients, 38 had been treated previously with
alendronate (10 mg/day or 70 mg/week), calcium (1000 mg/day), and
vitamin D (800 IU/day) for a minimum duration of 33 months (mean
63.6 months), and 28 were naïve to osteoporosis treatment. During
the 24-month study period, all patients self-administered once-dailysubcutaneous injections of teriparatide 20 μg; additionally, all patients
received daily calcium 1000 mg and vitamin D3 400–1200 IU.
2.2. Study measurements
Blood sampleswere collected in themorning, after an overnight fast,
at baseline and at 1, 3, 6, 12, and 24 months/study endpoint. The
samples were sent to a central laboratory where serum concentrations
of the bone formation markers, PINP and bone alkaline phosphatase
(B-ALP), and the bone resorption marker, type 1 collagen cross-linked
C-telopeptide (βCTX), were assessed. Intact PINP was measured by
radioimmunoassay (Procollagen Intact PINP, Orion Diagnostica,
Finland); the assay was not sensitive to the small molecular weight
degradation products of the propeptide. Intra-assay variance was
below 5% and inter-assay variance was below 7% at concentrations
between 20 and 90 μg/l. βCTX concentration was assessed using
electrochemiluminescence-based immunoanalysis (Elecsys 1010 Ana-
lyzer®, Roche Diagnostics GmbH, Germany). Detection limit was
b10 ng/l; intra- and inter-assay variance was below 5% and below 7%,
respectively, for samples with βCTX concentration N 500 ng/l, below
7% and below 9% for samples between 200 and 500 ng/l, and below
10% for samples b200 ng/l. B-ALP concentration was determined using
an immunoradiometric assay (Tandem-R Ostase®, Hybritech, Inc., San
Diego, CA, USA), with coefﬁcients of variation 4.2–6.8% and 7.4–7.9%
for intra- and inter-assay, respectively. Least signiﬁcant changes were
28%, 20% and 21% for βCTX, PINP and B-ALP, respectively.
BMDwasmeasuredwith a QDR4500 A bone densitometer (Hologic,
Inc., Waltham, MA, USA), with normative values provided by Hologic,
Inc. Short-term precision errors were 0.7% for the lumbar spine (L1–
L4) and1.9% for the femoral neck; long-termprecision error determined
with the Hologic phantom was 0.3%.
Amanual drill with a 7.5mmtrephine (Medical Innovations Interna-
tional, Inc., Rochester, MN, USA)was used to obtain transiliac crest bone
biopsies. The two biopsies performed for each patient were taken from
opposite sides of the body; the ﬁrst biopsywas obtained either from the
left or the right side, according to a random allocation scheme. Biopsies
were taken at baseline, before teriparatide initiation, and at the 24-
month endpoint, and were sent in 70% ethanol for assessment at a cen-
tral laboratory. Biopsies were considered complete and suitable for
analysis if they consisted of two well-deﬁned cortical tables from tetra-
cycline double-labeling and did not have any complete fractures be-
tween the cortices. High-resolution quantitative CT was performed on
specimens in 70% ethanol at room temperature, using a micro-CT scan-
ner (General Electric Enhanced Visions Systems, London, ON, Canada).
From scanning of the iliac crest biopsies, a three-dimensional (3D) re-
construction was produced using 22.6 μm isotopic voxels to ensure
identical resolution in all three orthogonal directions. Image gray-level
values for each specimen were calibrated using a cortical bonemimick-
ingmaterial standard (SB3, Gammex, RMI,Middleton,WI). Imageswere
thresholded into bone and non-bone voxels to measure bone density,
area, mineral content, and mineralization.
The biopsy specimens were processed, embedded, and sectioned, as
previously described [10]. Two-dimensional (2D) histological assess-
ment was performed on 5-μm thick biopsy sections stained with
McNeal's tetrachrome or left unstained. Active bone formation and re-
sorption were evaluated on the cancellous bone surface. Bone-forming
activity toward bridging the trabeculae was also assessed.
2.3. Statistics
The initial sample size was estimated to enable detection of a differ-
ence in active mineralizing surfaces between the treatment-naïve and
alendronate-pretreated groups. The present post hoc study used data
only frompatients who provided evaluable biopsies and evaluable sam-
ples for bone turnover markers at both baseline and the 24-month end-
point of teriparatide treatment. Differences between the treatment-
Table 1
Baseline characteristics of patients and serummarkers of bone turnover, by treatment pri-
or to teriparatide initiation.
Treatment-naïve
(n= 16)
Alendronate pretreated
(n= 29)
Age (years) 67.6 (7.0) 69.2 (7.3)
Time since menopause (years) 17.8 (6.8) 18.2 (7.8)
Prior alendronate therapy duration
(months)
– 64.5 (16.4)
Lumbar spine BMD (g/cm2) 0.70 (0.06) 0.77 (0.09)⁎
Femoral neck BMD (g/cm2) 0.60 (0.12) 0.60 (0.09)
Serum turnover markers
Procollagen type I amino-terminal
propeptide (μg/l)
48.9 (15.7) 26.0 (13.4)⁎⁎
Type 1 collagen cross-linked
C-telopeptide (ng/l)
430.7 (176.1) 221.6 (138.7)⁎⁎
Bone-speciﬁc alkaline phosphatase
(μg/l)
15.8 (3.6) 10.6 (4.6)⁎⁎
Data showmean (SD). Part of the baseline characteristics has been published elsewhere [10].
⁎ P b 0.01 for between-group difference.
⁎⁎ P b 0.001 for between-group difference.
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rank-sum tests, with no adjustment for confounders. Within-group
changes from baseline during teriparatide treatment were examined
using Wilcoxon signed-rank tests. Non-parametric analyses were used
due to the small sample size and the possibility of non-normality of
the data. Pearson correlation coefﬁcients were determined for evalua-
tion of correlations between bone turnover markers (absolute changes)
and bone microarchitecture indices (percentage changes), at baseline,
at endpoint, and for changes over time. For all of these exploratory anal-
yses, a P-value b 0.05 was considered statistically signiﬁcant.
3. Results
The baseline characteristics of the 29 alendronate-pretreated pa-
tients and 16 treatment-naïve patients who completed 24 months of
teriparatide treatment have been presented previously [10,21] and are
brieﬂy summarized in Table 1. Prior to teriparatide treatment, patients
pretreated with alendronate, for a minimum of 34 months to a maxi-
mumof 93months, had signiﬁcantly greater lumbar spine BMD and sig-
niﬁcantly lower concentrations of the bone turnover markers than the
treatment-naïve patients, as expected with long-term bisphosphonate
treatment.
Serum concentrations of PINP, βCTX, and B-ALP increased rapidly in
both groups after starting teriparatide treatment (Table 2). No signiﬁ-
cant differences were observed in serum marker concentrationsTable 2
Median serum concentrations of bone turnover markers by time of treatment with teriparatid
PINP (μg/l) βC
TN
(n= 16)
ALN
(n= 29)
TN
(n
0 months 48.9 22.6*** 42
3 months 92.5 92.7 53
6 months 120.6 150.4 66
12 months 142.3 174.1 64
24 months 77.3 96.0 48
Percentage change
0 to 12
191 529*** 70
P-value
0 to 12
b0.001 b0.001 0.0
Percentage change
0 to 24
108 340*** 39
P-value
0 to 24
0.001 b0.001 0.0
ALN = alendronate-pretreated; B-ALP = bone alkaline phosphatase; βCTX = type 1 collagen
treatment-naïve. P values are for within-group percentage changes from baseline; between-
***P b 0.001.between the treatment-naïve group and the alendronate-pretreated
group at any time after baseline. For PINP, the increase from baseline
to 24 months remained signiﬁcant for both the treatment-naïve and
the alendronate-pretreated groups, whereas the changes at both 12
and 24 months for βCTX and B-ALP were signiﬁcant only in the
alendronate-pretreated group. Themedian change at 12 and 24months
as a percentage of the baseline concentration was greater for PINP than
for βCTX and B-ALP.
The median percentage increase in lumbar spine BMD at 12 months
was 1.1% in the alendronate-pretreated group, which was not signiﬁ-
cantly different from baseline (P = 0.141). The percentage increase in
the treatment-naïve group was 6.2%, which was signiﬁcant versus
baseline (P b 0.001) and versus the alendronate-pretreated group
(P = 0.004). However, the percentage changes at 24 months were
signiﬁcantly different from baseline in both groups (P b 0.001 for
both), with no signiﬁcant between-group difference (treatment-naïve
10.2% versus alendronate-pretreated 5.3%, P= 0.077).
There were no signiﬁcant differences observed between the treat-
ment-naïve and alendronate-pretreated groups at baseline or at end-
point for any of the 2D or 3D microstructural parameters assessed
(Table 3), and no differences for change from baseline to endpoint ex-
cept for the change in 2D trabecular number which was greater in the
alendronate-pretreated patients (P = 0.040). The 3D bone volume
and trabecular thickness increased signiﬁcantly from baseline in both
the alendronate-pretreated group and in the treatment-naïve group.
The increase of 2D trabecular width reached the level of statistical sig-
niﬁcance in the alendronate-pretreated group only, while 2D trabecular
separation increased in the treatment-naïve group.With this exception,
the observed increases in trabecular number and separation were not
statistically signiﬁcant.Micro-CT and isosurface imaging from the 3D re-
constructions of a representative pair of biopsies with or without
alendronate pre-treatment (Fig. 1) showed a denser structure to the
bone following 24 months of teriparatide treatment in both groups.
The images showed an increase in active bone formation (Fig. 2), and
greater osteoblast recruitment and activity, as indicated by the labeling
surface and the double-labeling distance with tetracycline (Fig. 3) in
both treatment-naïve and alendronate-pretreated patients. An increase
in trabecular connectivity was shown by the bridging between the tra-
beculae following 24 months of teriparatide treatment (Fig. 4).
Pearson correlations between the bone turnover marker concentra-
tions and the 3D microstructure indices showed no signiﬁcant correla-
tions at baseline in the alendronate-pretreated group (data not
shown). For the treatment-naïve patients at baseline, both PINP
(r=−0.535, P=0.033) andβCTX (r=−0.571, P=0.021) concentra-
tionswere inversely correlatedwith trabecular thickness. No signiﬁcante in treatment-naïve and alendronate-pretreated patients.
TX (ng/l) B-ALP (μg/l)
= 16)
ALN
(n= 29)
TN
(n= 16)
ALN
(n= 29)
7.6 179.7*** 16.8 9.8***
6.4 634.8 14.3 13.1
3.3 812.7 16.1 17.7
6.5 753.8 20.0 18.8
7.7 545.9 14.5 16.6
297*** 26 84*
08 b0.001 0.051 b0.001
197** −5 67**
93 b0.001 0.632 b0.001
cross-linked C-telopeptide; PINP = procollagen type I amino-terminal propeptide; TN =
group differences at speciﬁed times in the study are shown as *P b 0.05, **P b 0.01, and
Table 3
Two- and three-dimensional histomorphometry indices of cancellous bone microarchitecture at baseline and after 24 months of teriparatide treatment in patients who were previously
treatment-naïve or had received alendronate pretreatment.
Treatment-naïve
(n= 16)
Alendronate pretreated
(n= 29)
All
(n= 45)
Baseline 24 Months Baseline 24 Months Baseline 24 Months
Mean (SD) % Change (SD) P-value Mean (SD) % Change (SD) P-value Mean (SD) % Change (SD) P-value
Two dimensional (2D)
Bone area/total area (B·Ar/Tt. Ar, %) 20.1 (5) −3.6 (30) 0.273 19.0 (6) 33.2 (66) 0.016 19.5 (5) 19.6 (58) 0.138
Trabecular width (Tb·Wi, μm) 0.14 (0.03) 7.0 (24) 0.273 0.14 (0.03) 19.6 (35) 0.033 0.14 (0.03) 14.9 (32) 0.018
Trabecular number (Tb·N, mm−1) 1.4 (0.3) −9.9 (14) 0.068 1.3 (0.3) 8.0 (28) 0.l63 1.4 (0.3) 1.3 (25) 0.810
Trabecular separation (Tb·Sp, μm) 0.58 (0.12) 15.2 (20) 0.017 0.64 (0.20) −3.4 (39) 0.126 0.62 (0.17) 3.5 (34) 0.798
Three dimensional (3D)
Bone volume/tissue volume (BV/TV, %) 17 (6) 105 (356) 0.039 18 (8) 55 (139) 0.005 18 (7) 73 (237) b0.001
Trabecular thickness (Tb·Th, μm) 0.12 (0.03) 30.4 (30) b0.001 0.13 (0.03) 30.8 (53) b0.001 0.12 (0.03) 30.7 (46) b0.001
Trabecular number (Tb·N, mm−1) 1.47 (0.43) 36.7 (179) 0.298 1.44 (0.55) 12.7 (54) 0.254 1.45 (0.51) 21.2 (114) 0.637
Trabecular separation (Tb·Sp, μm) 0.89 (1.40) 3.1 (36) 0.706 0.71 (0.49) 10.4 (75) 0.237 0.77 (0.91) 7.8 (64) 0.439
Fig. 1. Teriparatide improved trabecular structure in both treatment-naïve and alendronate-pretreated patients. The representative images are from three-dimensional reconstruction of
high-resolution quantitative tomography scans of paired iliac crest biopsies from the same patients at baseline and after 24 months of teriparatide treatment. Teriparatide treatment
increased bone volume and trabecular thickness.
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Fig. 2. Teriparatide stimulated bone anabolic response in both treatment-naïve and alendronate-pretreated patients. The representative images of paired iliac crest biopsies, stained with
McNeal's tetrachrome, from the same patients, demonstrate an increase in osteoblast number (arrowed) and the osteoid surface area (arrowed) in both treatment-naïve and alendronate-
pretreated patients.
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24 months of teriparatide and 24-month trabecular microstructure
indices in the alendronate-pretreated group (data not shown). For
patients overall, 24-month PINP and βCTX were correlated with 24-
month trabecular thickness (PINP r = 0.340, P = 0.026; βCTX r =
0.346, P = 0.023), and in the treatment-naïve group 24-month βCTX
was correlated with 24-month trabecular thickness (r = 0.556, P =
0.025); therewere no signiﬁcant correlationswith othermicrostructure
indices at 24 months (data not shown).
In the alendronate-pretreated patients, the 3-month change in PINP
did not correlate with 24-monthmicrostructural changes, while the 12-
month PINP changes were signiﬁcantly correlated. Scatter plots
showing BV/TV changes versus PINP changes at 3 and 12 months are
shown in Fig. 5. Similarly to PINP, no meaningful correlations of 3-
month βCTX changes could be observed, but 12-month βCTX changes
correlated with microstructural improvement in the alendronate-
pretreated patient group (Table 4). Respective correlations with B-ALP
were not meaningful (data not shown).
4. Discussion
This is the ﬁrst study to indicate that teriparatide treatment im-
proves cancellous bone microstructure irrespective of antiresorptive
pretreatment. The improvement in cancellous bone microstructure
was consistent with changes observed in paired biopsies of previously
treatment-naïve postmenopausal women treated with either
teriparatide 20 or 40 μg for a mean of 19 months [16]. This was also in
agreement with earlier studies with parathyroid hormone fragments
and various treatment regimes, which indicated an anabolic effect on
cancellous bone microarchitecture [22–24]. Other investigations did
not ﬁnd a signiﬁcant effect on cancellous bone, probably due to insufﬁ-
cient sample size [25,26]. Our data conﬁrm the anabolic effect of
teriparatide on cancellous bone microstructure, which extends ourearlier ﬁndings concerning signs of increased cortical bone formation
in the identical biopsies [21].
We found no signiﬁcant differences in the anabolic response of can-
cellous bone between patients naïve to antiresorptive treatment and
those pretreated with the potent antiresorptive alendronate. The large
variability of the results, however, does not allow us to address this
issue with certainty. Some earlier ﬁndings suggested that initial bone
formation by teriparatide was inﬂuenced by the level of bone turnover
at the time of initiation. Teriparatide-induced bone turnover and BMD
increase were shown to occur earlier and to a greater extent in patients
with higher baseline bone turnover who were pretreated with the less
potent antiresorptive raloxifene when compared with patients with
more reduced baseline bone turnover due to pretreatment with
alendronate [20]. Similar ﬁndings were reported with regard to
risedronate or alendronate pretreatment [27], and no or diverse
antiresorptive pretreatment [7]. In agreement with the present micro-
structural results, dynamic histomorphometric indices on the cancel-
lous bone surface of the investigated biopsies have demonstrated a
distinctly suppressed bone turnover in the alendronate-pretreatment
group at baseline, with almost no differences between the two treat-
ment groups at the end of 24 months of teriparatide treatment [10].
Thus, longer-term teriparatide treatment could override any initial in-
hibitory effect of antiresorptive pretreatment. Similar conclusions
could be drawn from the respective BMD increase after 24 months of
teriparatide treatment [7].
In thepresent study, the 12-month increases of PINP andβCTX in the
alendronate-pretreated group were correlated with improvements of
cancellous bonemicrostructure after 24months. Our studywas not suf-
ﬁciently powered to investigate properly the correlations in the smaller
treatment-naïve patient group. When the two groups were pooled for
these correlation analyses, the results were not different from those ob-
tained for the alendronate-pretreated group (data not shown). Correla-
tions between increases in biochemical markers of bone turnover and
Fig. 3. Teriparatide stimulated bone mineralization in both treatment-naïve and alendronate-pretreated patients. The representative images of paired iliac crest biopsies, from the same
patients at baseline and after 24months of teriparatide treatment, demonstrate active bone formation, indicated by tetracycline ﬂuorochrome labels (arrowed), on bone surfaces in both
treatment-naïve and alendronate-pretreated patients after 24 months of teriparatide treatment in comparison with baseline.
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treatment without antiresorptive pretreatment have been extensively
studied (reviewed by Krege et al. [9]). Most of the signiﬁcant correla-
tions were demonstrated between a short-term (1 to 6 months) in-
crease in PINP and an increase in BMD at 1 to 2 years [14,15,17,28–
31]. One study showed correlations between bone marker increases
(procollagen I C-terminal propeptide and B-ALP) and microstructural
improvement in paired biopsies of the iliac crest [3]. Several same-
time cross-sectional correlations between biochemical markers of
bone formation and dynamic histomorphometric indices such as the
mineralizing surface indicate that biochemical markers are reliable sur-
rogates of the level of bone formation on the bone surface of patients
treated with teriparatide. For example, PINP concentration correlated
with mineralizing surface in iliac bone biopsies after 6 months of
teriparatide treatment [31]. Similarly, in the current study, PINP, βCTX,
and B-ALP correlated signiﬁcantly with diverse dynamic
histomorphometric markers (osteoid, osteoblast and mineralizing sur-
faces, and activation frequency) prior to and after 24 months of
teriparatide treatment [10]. In line with the earlier ﬁndings that BMD
improvements are predicted by PINP, the present data indicate that in-
creases in PINP and βCTX are associated with microstructural improve-
ment in patients treated with teriparatide.
In the present study, the increases in turnovermarkers were already
evident after 1 month of teriparatide treatment in the alendronate-pretreated group, for whom bone turnover had been initially sup-
pressed. Earlier observations in the European Study of Forsteo
(EUROFORS) also indicated a sharp increase in thesemarkers in patients
receiving teriparatide who were pretreated with antiresorptives. After
1 month on teriparatide, the increase in PINP was signiﬁcantly more
pronounced in the treatment-naïve group than in the alendronate-
pretreated group, but no difference was evident after 6 months [14,
32]. Similarly, other studies found only a transitional delay on
teriparatide-induced bone turnover increase in patients, as a function
of suppressed bone turnover at baseline [19,27]. Overall, the evidence
from numerous studies suggests a mild and transitional impact, with
limited clinical importance, of antiresorptive pretreatment on bone
turnover during subsequent teriparatide therapy.
Changes in PINP and βCTX concentrations at 1 or 3 months did not
appear to predict cancellous bone microstructural changes after
24 months of teriparatide treatment. Baseline PINP concentration and
changes up to 6 months have previously been reported to correlate
with changes in BMD and bone strength [8,9,11,13–15]. The lack of pre-
dictive value of 1 and 3-month changes in PINP and βCTX concentration
on changes of cancellous bone microstructure indices was different
from the signiﬁcant correlations of bone marker concentrations with
dynamic histomorphometric markers found previously in this study
[10]. However, the slopes of the correlations of bone turnover markers
and dynamic markers were previously noted to increase with duration
Fig. 4. Teriparatide induced trabecular connectivity in both treatment-naïve and alendronate-pretreated patients. The representative images from iliac crest biopsies after completion of
24months of teriparatide treatment demonstrate newly formedbone that is going to bridge (A and B, bone sections stainedwithMcNeal's tetrachrome) or has bridged (C andD, unstained
bone sections) the adjacent trabeculae (arrowed) in treatment-naïve (A and C) and alendronate-pretreated (B and D) patients.
22 A. Fahrleitner-Pammer et al. / Bone 89 (2016) 16–24of teriparatide treatment [10]. It is possible that the high variability in
cancellous bone indices and the comparatively small sample size
masked any correlations at early times.
No correlation between the 3-month increase in PINP and micro-
structural improvement was evident in the alendronate-pretreatment
group, even though the PINP increase was signiﬁcant in both patient
groups at this time point. Because the increases in bone turnover
markers peaked at around 12 months, the changes at 12 months may
be the most sensitive to predict improvements in cancellous bone
microstructure, especially in patients with long-term antiresorptive
pretreatment. Errors in measurement, both of PINP and of
microarchitecture, could mask a stronger true relationship between
these variables than we have demonstrated. Like all histomorphometry
studies, there was a limited sample size, especially in the treatment-
naïve group, and signiﬁcant variability of the individual responses, so
the inter-individual differences between changes in microstructural in-
dices was large. Until additional data are available, we suggest
interpreting these results with caution.Fig. 5. Scatter plots showing the changes in procollagen type I amino-terminal propeptide (PINP
P=0.006) and 24-month changes in bone volume/tissue volume (BV/TV)with teriparatide trea
688% is not shown. The analysis results with or without inclusion of this data-point were not dThe strongest correlation between changes in PINP and microstruc-
tural indices was observed with BV/TV, which was the primary bone
histomorphometrymeasure that increased themost during teriparatide
treatment. A numerically smaller, but signiﬁcant, increase of trabecular
thickness, another primary measure, was also observed with
teriparatide treatment. However, the lower magnitude of this change
was probably not sufﬁcient to result in signiﬁcant correlations between
trabecular thickness and PINP changes. Trabecular number and trabec-
ular separation are derived from BV/TV and trabecular thickness as sec-
ondary measures [33] and had variable levels of correlation with PINP.
Therefore, similar to earlier ﬁndings, our study was not powered to de-
tect correlations with high certainty between individual cancellous
microarchitectural indices and PINP changes on teriparatide [3,16].
This study had several limitations. It was an open-label study in
which all patients were assigned to teriparatide treatment. The relative-
ly small sample size, when compared with larger cohorts, limited the
conclusions regarding the changes in biochemical markers. Only valid
biopsies could be used for analysis and the number of paired biopsies) concentration from baseline to 3 (A; r=0.152, P=0.430) and 12months (B; r=0.502,
tment in patients whowere alendronate-pretreated. One data-pointwith BV/TV change of
ifferent (data not shown).
Table 4
Correlations (r values) between percentage changes in three-dimensional indices of cancellous bonemicrostructure after 24months of teriparatide and changes in PINP and βCTX after 3
and 12 months of teriparatide in patients pretreated with alendronate (n= 29).
Procollagen type I amino-terminal
propeptide (PINP)
Type 1 collagen cross-linked C-telopeptide
(βCTX)
3 months 12 months 3 months 12 months
Bone volume (BV/TV) 0.152 0.502⁎⁎ 0.249 0.378⁎
Trabecular thickness (Tb·Th) 0.273 0.351 0.284 0.164
Trabecular number (Tb·N) 0.070 0.559⁎⁎ 0.212 0.515⁎⁎
Trabecular separation (Tb·Sp, μm) 0.074 −0.432⁎ −0.235 −0.530⁎⁎
Values show Pearson correlation coefﬁcients.
⁎ P b 0.05 for correlation.
⁎⁎ P b 0.01 for correlation.
23A. Fahrleitner-Pammer et al. / Bone 89 (2016) 16–24was less in the treatment-naive than in the alendronate-pretreated
group, limiting the statistical power to detect signiﬁcant changes and
correlations, especially differences between treatment-naïve and
alendronate-pretreated groups.
5. Conclusions
The present analysis shows that cancellous bone microstructure is
signiﬁcantly improved with teriparatide treatment, whether or not pa-
tients receive antiresorptive pretreatment. Additionally, changes in
PINP show correlations with cancellous bone microstructure indices at
24 months in treatment-naïve patients and in those who have been
pretreated with alendronate. The results warrant further research on
the clinical value of PINP changes for predicting subsequent improve-
ments in cancellous bone microstructure in patients receiving
teriparatide.
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